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AbstrAct
Introduction We present the protocol for a multifactorial 
intervention study designed to test whether individualised 
treatment, based on pathophysiological phenotyping and 
individualised treatment goals, improves type 2 diabetes 
(T2D) outcomes.
Methods and analysis We will conduct a prospective 
controlled multicentre open-label intervention study, 
drawing on the longitudinal cohort of the Danish Centre 
for Strategic Research in Type 2 Diabetes (DD2). New 
clinically diagnosed patients with T2D in the intervention 
group will be assigned to receive individualised treatment 
by their general practitioner. Intervention patients will be 
compared with a matched control cohort of DD2 patients 
receiving routine clinical care. Among intervention patients, 
we will first do pathophysiological phenotyping to classify 
patients into WHO-defined T2D or other specific types 
of diabetes (monogenic diabetes, secondary diabetes 
etc). Patients with WHO-defined T2D will then be further 
subcharacterised by their beta-cell function (BCF) and 
insulin sensitivity (IS), using the revised homeostatic 
assessment model, as having either insulinopaenic T2D 
(high IS and low BCF), classical T2D (low IS and low 
BCF) or hyperinsulinaemic T2D (low IS and high BCF). 
For each subtype, a specific treatment algorithm will 
target the primary pathophysiological defect. Similarly, 
antihypertensive treatment will be targeted at the specific 
underlying pathophysiology, characterised by impedance 
cardiography (relative importance of vascular resistance, 
intravascular volume and cardiac inotropy). All treatment 
goals will be based on individual patient assessment of 
expected positive versus adverse effects. Web-based 
and face-to-face individualised lifestyle intervention will 
also be implemented to empower patients to make a 
sustainable improvement in daily physical activity and to 
change to a low-carbohydrate diet.
Ethics and dissemination The study will use well-known 
pharmacological agents according to their labels; patient 
safety is therefore considered high. Study results will be 
published in international peer-reviewed journals. 
trial registration number NCT02015130; Pre-results.
IntroductIon
Importance of individualised glycaemic control
Although current advances in type 2 
diabetes (T2D) treatment have reduced 
mortality1 and possibly complications2 
among patients with T2D, they still 
suffer excess mortality compared with 
people without diabetes.3 Poor glycaemic 
control has been linked to cardiovas-
cular morbidity, even below the threshold 
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Protocol
strengths and limitations of this study
 ► The ‘Individualised treatment of newly clinical 
diagnosed T2D in general practice’ study is a 
nationwide intervention study in primary care, based 
on a close cooperation between hospital-based 
diabetes specialists and general practitioners.
 ► Endocrinological assessment of pathophysiological 
phenotypes will form the basis for individual 
treatment algorithms, made readily available to 
primary healthcare providers.
 ► The study will clarify if an individualised approach to 
the pharmacological and lifestyle treatment of T2D 
with individualised treatment goals is associated 
with a range of improved hard outcomes in everyday 
clinical practice, including microvascular and 
macrovascular complications and death.
 ► The study is not randomised, and potential differences 
in prognostic factors between intervention and 
control patients need to be addressed by rigorous 
statistical methods.
 ► Existing high-quality healthcare registries will be 
used for assessment of outcomes, rather than 
primary adjudication of endpoints. 
group.bmj.com on December 15, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Stidsen JV, et al. BMJ Open 2017;7:e017493. doi:10.1136/bmjopen-2017-017493
Open Access 
for diabetes,4 although increased mortality is also 
seen in the lowest 10th percentile of haemoglobin 
A1c (HbA1c) values.5 This has led to several trials 
testing intensive glucose-lowering against moderate 
glucose-lowering strategies.6–8 Their results have been 
inconclusive, and a meta-analysis of trials of inten-
sive glucose lowering found no effect on mortality 
(risk ratio (RR) 1.04, 0.91–1.19) or cardiovascular 
mortality (RR 1.11, 0.86–1.43). A significant effect 
(RR 0.85, 0.74–0.96) was observed for non-fatal 
myocardial infarction, although in analyses restricted 
to high-quality studies, there was no favourable effect 
for any myocardial infarction (RR 1.34, 0.77–2.35). In 
addition, a potential effect was observed for new or 
worsening retinopathy (RR 0.85, 0.71–1.03).9 10 On 
the other hand, intensive glucose control was asso-
ciated with a significant increase in severe hypogly-
caemic events (RR 2.33, 1.62–3.36).9 The analysed 
trials are heterogeneous with respect to diabetes 
duration among included patients and achieved 
HbA1c. In the UK Prospective Diabetes Study, inten-
sive glucose lowering to an HbA1c of 7.0% in newly 
diagnosed T2D was associated with reduced all-cause 
mortality,11–13 and this has recently been confirmed 
in an observational study design.14 Intensive glucose 
lowering of HbA1c to 6.4% in the The Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) 
trial among patients with longer duration of diabetes 
was associated with an increased risk of all-cause and 
cardiovascular mortality.6 15 Post hoc analyses of The 
Action in Diabetes and Vascular Disease: Preterax 
and Diamicron Modified Release Controlled Eval-
uation (ADVANCE) study, which sought to deter-
mine the effect on cardiovascular disease (CVD) of 
intensive glucose-lowering compared with standard 
glucose-lowering treatment, have shown that patients 
with severe hypoglycaemic events have a higher inci-
dence of microvascular and macrovascular events as 
well as mortality.16 Together, these results indicate the 
necessity for an individualised approach, with differ-
entiated goals for glycaemic control. A tight glycaemic 
goal of 48 mmol/mol seems relevant for many patients 
with newly diagnosed T2D, while patients with former 
CVD, neuropathy or high risk of hypoglycaemic events 
arguably could aim for an HbA1c below 58 mmol/
mol.17 Frail patients should aim for relief of hypergly-
caemic symptoms and treatment should confer a very 
low hypoglycaemic risk.17 
Non-vascular outcomes in T2D become increas-
ingly important these years. The incidence of cancer 
overall and of several specific cancers is substantially 
increased in patients with T2D compared with persons 
without diabetes,18 19 and also mortality from cancer is 
increased.20 Whether specific glucose-lowering thera-
pies are associated with increased or reduced risk of 
cancer remains uncertain. A meta-analysis has reported a 
possibly reduced cancer risk with metformin and thiazo-
lidinedione therapy, and an increased risk with insulin, 
sulfonylurea and alpha glucosidase inhibitor use. When 
the meta-analysis was restricted to randomised controlled 
trials (RCTs), these associations could not be confirmed, 
with the limitation that most RCTs are too short to 
properly elucidate cancer risk and have heterogeneous 
comparators.21 These uncertainties highlight the need 
for long-term evaluation of therapy not only with regard 
to microvascular and macrovascular disease but also with 
respect to cancer risk.
Improved glycaemic control through better pathophysiological 
phenotyping
Diabetes is classified into type 1 diabetes, T2D, other 
specific types of diabetes and gestational diabetes.22 It 
has become increasingly clear that diabetes is a more 
heterogeneous disease.23 Data from the Danish Centre 
for Strategic Research in Type 2 Diabetes (DD2) show 
that in clinical practice, patients with other specific 
types of diabetes than T2D (for example, glucocorti-
coid-induced diabetes, late autoimmune diabetes of the 
adult or secondary diabetes) are often misclassified as 
patients with classical WHO-defined T2D. As the patho-
physiology of other specific types of diabetes is poten-
tially different from classical WHO-defined T2D,24 poor 
glycaemic control could be a consequence if the given 
treatment does not address the underlying pathophysi-
ological defect. Moreover, DD2 data also show that the 
classical WHO-defined T2D population is heterogeneous 
and may be further classified according to pathophysio-
logical phenotypes, with potential implications for appro-
priate glucose-lowering treatment.25 In addition, ethnic 
differences in the pathophysiology of T2D have been 
reported,26 27 underlining the importance of both inter-
ethnical and intraethnical heterogeneity in T2D.
Importance of individualised blood pressure control
Elevated blood pressure in patients with T2D is associ-
ated with cardiovascular death, starting with a systolic 
blood pressure of 120 mm Hg.28 A recent meta-analysis 
concluded that when systolic office blood pressure was 
below 140 mm Hg, further reduction in blood pressure 
was associated with increased risk of cardiovascular death 
in patients with diabetes.29 However, even under optimal 
conditions, blood pressure control is very difficult to 
achieve, with only 50% of patients reaching a systolic 
blood pressure below 140 mm Hg.30 Impedance cardi-
ography has been shown to increase the proportion of 
patients who achieve blood pressure control.31 A recent 
study in a specialised hypertension clinic could not repli-
cate this finding, although the incidence of adverse events 
was significantly reduced in patients in the impedance 
group.32 Impedance cardiography offers an assessment of 
cardiac contractility, vascular resistance and intravascular 
volume. In the ‘Individualised treatment of newly clinical 
diagnosed T2D in general practice’ (IDA) study, these 
estimates will be used to guide selection of antihyperten-
sive treatment in order to obtain better blood pressure 
control and to reduce side effects.
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Table 1 Data sources
Variables Source Intervention Control
Baseline biochemical measurements from whole blood, 
plasma and urine (eg, C-peptide and Glutamic Acid 
Decarboxylase antibodies (GAD-ab))
DD2 biobank Yes Yes
DNA samples DD2 biobank Yes Yes
Baseline clinical variables (smoking, physical exercise, 
alcohol consumption)
DD2 interview Yes Yes
Longitudinal clinical biochemical measurements 
(HbA1c, lipids, s-creatinine, urine albumin–
creatinine ratio)
Danish Diabetes Database for Adults Yes Yes
Longitudinal clinical measures (BMI, 
waist circumference, blood pressure, smoking)
Danish Diabetes Database for Adults Yes Yes
Medical history at baseline (hospital contact history) The Danish National Patient Register Yes Yes
Medical events during the study (hospital contacts) The Danish National Patient Register Yes Yes
Medication prior to baseline The Danish National Prescription 
Registry
Yes Yes
Medication during the study The Danish National Prescription 
Registry
Yes Yes
Intended medication National electronic medicine chart 
Fælles medicinkort (FMK)
Yes Yes
Socioeconomic variables Statistics Denmark Yes Yes
Quality of life at baseline and longitudinally DD2 Yes Yes
Cardiovascular surrogate markers obtained at IDA 
examinations
Study measurements Yes No
Daily physical activity at IDA examinations Study measurements Yes No
Patient-reported medical history and medication use Study interview Yes No
Cardiac impedance Study measurement Yes No
Blood pressure and HbA1c goal DD2 Yes Not relevant
BMI, body mass index; DD2, Danish Centre for Strategic Research in Type 2 Diabetes; HbA1c, haemoglobin A1c; IDA, Individualised 
treatment of newly clinical diagnosed T2D in general practice study.
Importance of individualised lifestyle changes
Lifestyle changes are the first-choice treatment for 
patients with newly diagnosed T2D. However, such 
changes are often difficult to implement and also costly 
if they need to be supervised. Promoting individualised 
lifestyle changes will be an important part of this study. 
Our aim is to provide evidence-based lifestyle interven-
tions that are feasible to implement on an everyday basis. 
We hope to empower patients to implement changes in 
their everyday life via face-to-face consultations and novel 
individualised supportive E-health solutions. We plan to 
identify and describe patients who will benefit clinically 
from the E-health solutions being offered and to use this 
knowledge for large-scale implementation of individual-
ised E-health technology in daily clinical practice.
Importance of multifactorial management of t2d
The Steno 2 study underlined the importance of multifac-
torial intervention in longer-standing T2D with a marked 
and durable reduction in morbidity and mortality asso-
ciated with multifactorial intervention.1 A multifacto-
rial approach is also emphasised in the current diabetes 
guidelines.17 33 In the current study, we therefore aim to 
develop specific individualised approaches to the various 
components of a multifactorial intervention.
Importance of diabetes management in general practice
Primary healthcare providers have an integrated knowl-
edge of the medical history, social status and family 
relationships of their patients, together with a general 
knowledge of treatment. IDA is designed to integrate 
specialist knowledge and examinations into the treatment 
of patients in primary care. Endocrinological assessment 
of pathophysiological phenotypes will form the basis for 
individual treatment algorithms, made readily available 
to primary healthcare providers.
HypotHEsIs
We hypothesise that individualised treatment based on 
pathophysiological traits and a new guidance strategy will 
improve glycaemic and blood pressure regulation and 
reduce complications in patients with clinically diagnosed 
T2D compared with outcomes under current guidelines. 
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Figure 1 Study timeline.
Figure 2 Recruitment flowchart at general practitioner (GP) 
level. DD2, Danish Centre for Strategic Research in Type 
2 Diabetes; IDA, Individualised treatment of newly clinical 
diagnosed T2D in general practice study.
We hypothesise that individualised treatment will reduce 
side effects and polypharmacy, thereby improving patient 
compliance and quality of life. Furthermore, we hypothe-
sise that an individually tailored approach has the poten-
tial to improve the cost–benefit ratio of T2D treatment.
AIM
The study’s aim is to investigate the effect of a new treat-
ment concept for patients with T2D based on personalised 
treatment in general practice supervised by specialists. 
Treatment goals, lifestyle interventions and pharmacolog-
ical treatment will be individualised. Medication choices 
will be based on pathophysiological measurements of 
possible underlying causes of hyperglycaemia and hyper-
tension in individual patients.
objEctIvEs
The primary objective of the study is to assess the effect of 
individualised, multifactorial, interactive and supervised 
treatment in patients with T2D compared with treatment 
based on contemporary guidelines. The composite clin-
ical outcome measure will encompass all-cause mortality, 
microvascular and macrovascular complications, cancer 
and hypoglycaemia. Secondary objectives are to assess 
effects on individual clinical outcomes, socioeconomic 
costs and quality of life.
MEtHods And AnAlysIs
setting and design
The study is designed as a prospective controlled multi-
centre open-label study of a controlled intervention in the 
longitudinal DD2 cohort. Newly diagnosed patients with 
T2D are enrolled prospectively in the population-based 
DD2 cohort. At baseline, the DD2 project collects inter-
view data and biobank blood and urine samples.34 35 
Following enrolment, each participant is followed over 
time using data in nationwide registries.36 The registries 
have documented high validity.37–39 The collected data in 
the study are summarised in table 1. This study is one of 
several planned studies drawing on the cohort.40
The study setting will be community based. Patients in 
the intervention group will be recruited and treated by 
their general practitioners (GPs). Patients in the control 
group will be passive study participants, followed longi-
tudinally using information from the DD2 cohort and 
biobank41 and linked longitudinally to national registries. 
The biobank contains whole blood, plasma, DNA and 
urine samples. Patients in the intervention group will be 
recruited over 3 years, with clinical examinations at base-
line and after 2, 4 and 10 years. The project timeline is 
shown in figure 1.
The project builds on the concept of shared care, 
where specialist knowledge is expanded into the 
primary care sector. For GPs participating in the study, 
specialist input regarding the patient’s phenotype and 
the recommended individualised treatment hereof will 
be delivered electronically to each patient’s electronic 
health record at initiation and regularly during the 
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Figure 3 Recruitment (A) and general practitioner (GP) contacts in the intervention group (B). DD2, Danish Centre for Strategic 
Research in Type 2 Diabetes; IDA, Individualised treatment of newly clinical diagnosed T2D in general practice study; OPC, 
Outpatient clinic; T2D, type 2 diabetes.
study. Specialist counselling is also available by phone 
during the day.
patients and recruitment
A flowchart of GPs participating in DD2 and IDA 
is provided in figure 2. Patients in the intervention 
group will be recruited from GPs in the region of 
southern Denmark and the region of Zealand partic-
ipating in both the DD2 cohort and the IDA study. 
Patients in the control group will be recruited from 
GPs participating in the DD2 cohort but not in the 
IDA study. The selection process for patients in the 
two groups will be different and adjustment for differ-
ences in prognostic factors at baseline is therefore 
warranted as described in the statistical section.
Intervention patients
A flowchart of recruitment is provided in figure 3A. 
Participating IDA GPs will be responsible for the initial 
patient contact, including collection of brief general 
patient information. If a DD2 patient is interested in 
the study, the GP automatically will register the patient 
in the DD2 website, triggering contact by a study nurse 
who will give the patient detailed study information. This 
will occur either by phone or during an initial informa-
tional meeting. Collection of in-depth patient informa-
tion, informed consent and additional screening will 
take place at central study hospitals prior to the baseline 
examination.
The following patient inclusion criteria will be used:
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 ► Member of the DD2 cohort.42
 ► Patient at a GP participating in the IDA study.
 ► Not diagnosed with type 1 diabetes, defined as age <30 
years at DD2 enrolment, fasting C-peptide <300 pM 
and GAD65-ab >20 IU/mL (see below).
 ► Life expectancy above 2 years.
 ► No participation in other clinical trials.
 ► Willing to provide written informed consent.
Control patients
Patients for the control group will be recruited from DD2 
clinics throughout Denmark not participating in the IDA 
study (figure 2). Availability of valid biobanked samples 
for measuring GAD-ab, P-glucose and C-peptide will be 
required to join the control group. As the control group 
will be created within DD2, neither GP nor patient will 
be informed, ensuring that the control group is truly 
blinded.
patient examination in the intervention group
Screening will take place at the following four central study 
sites: Odense University Hospital, Hospital of Southwest 
Denmark, Næstved Lægecenter and Holbæk Hospital. A 
written informed consent will be signed at the baseline 
visit prior to initiating examination of study participants.
Phenotype evaluation will be performed at the central sites 
at baseline and after 24 and 48 months. Medical history, 
medication use and measures used in the phenotype eval-
uation will be obtained from the patient. Fasting plasma 
glucose, GAD65-antibody and fasting C-peptide will be 
ascertained from the DD2 database. Repeat measures 
of cardiac impedance and unobserved automated blood 
pressure will be taken at the central sites at the following 
time points, determined by prior blood pressure values:
 ► Blood pressure (BP) ≤135/85 mm Hg: impedance 
measurement repeated after 24 months.
 ► 135/85 mm Hg<BP≤145/95 mm Hg: impedance 
measurement repeated after 12 and 24 months.
 ► BP >145/95 mm Hg: impedance measurement 
repeated after 6, 12 and 24 months.
The results of the phenotype evaluation for each specific 
patient will be assessed at Odense University Hospital and 
the patient-specific protocol recommendations sent to 
the patient’s GP via the electronic health record.
Treatment and implementation of the phenotype evaluation 
will take place at the GP’s office every third month or at 
the discretion of the GP (figure 3B). The GP will measure 
HbA1c, the lipid profile, the albumin–creatinine ratio, 
creatinine and BMI annually. The GP will report treat-
ment goals and any reasons for protocol deviations 
annually.
Daily physical activity
To measure daily physical activity level, a Axivity AX3 
accelerometer (Axivity, Newcastle, UK) will be taped 
on the thigh and on the lower back. The AX3 is an 11 g 
and 23×32.5×7.6 mm weatherproof accelerometer with a 
512 MB internal memory and clock. Accelerometers will 
be fixed directly on the skin using waterproof taping. 
Subjects will be instructed to wear the accelerometers 
at all times (including water activities and sleep) during 
a 10-day period and additional tape will be provided 
to patients at examination. The accelerometer on the 
back will be placed on the right side, above the upper 
point of the posterior iliac crest and next to the spine 
with its positive x-axis pointing downward and its nega-
tive z-axis pointing forward. The accelerometer on the 
thigh will be placed on the medial front of the right 
thigh, midway between the hip and knee joints, with its 
positive x-axis pointing downward and its negative z-axis 
pointing forward. A sampling rate of 50 Hz will be used 
and data stored in the original cwa Axivity file format, but 
also converted into a binary gt3x compatible file format 
using a custom-made add-on to OmGui Axivity software. 
Accelerometer wear time has recently been reported to 
be high.43 Patients will be closely instructed how to reat-
tach the accelerometer in case it falls off.
Cardiovascular surrogate markers
Patients with clinically diagnosed T2D within 2 years of 
their baseline examination will be invited to participate 
in additional evaluation of the following cardiovascular 
surrogate markers:
1. 24-hour ambulatory blood pressure monitoring 
(24ABPM)
 – 24ABPM will be implemented by means of bra-
chial oscillometric measurements, using the Mo-
bil-O-Graph system (IEM, Stolberg, Germany). 
The device will be set to measure BP every 15 min 
during the day (07:00–23:00) and every 30 min 
during the night (23:00–07:00). The patient will 
be instructed to record when s/he went to bed 
and got up.
2. Skin autofluorescence (SAF) to evaluate advanced gly-
cosolated end-products
 – SAF will be measured using the AGE Reader (Di-
agnOptics Technologies, Groningen, The Neth-
erlands). Technical details of this non-invasive 
device have previously been described in detail.44
3. Low-dose non-contrast CT scan to detect coronary ar-
tery calcification
 – The atherosclerotic plaque burden in the coro-
nary, carotid, aortic and femoral arteries will be 
estimated by measuring calcium during a 64-slice 
CT scan (Discovery VCT; GE Healthcare, Milwau-
kee, Wisconsin, USA) conducted at Odense Uni-
versity Hospital. The scan will be performed with 
the following parameters: gantry rotation time 500 
ms, 16×2.5 mm collimation, 120 kV tube voltage, 
200 mA tube current and a prospectively ECG-trig-
gered scan acquisition gating at 50% of the R–R 
interval. Scan data will be acquired during an 
inspiratory breath hold. The coronary artery cal-
cium (CAC) Agatston score is computed by sum-
ming the CAC scores of all foci in the epicardial 
coronary system.
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4. Ultrasound of the carotid arteries to evaluate intima–
media thickness (IMT) and plaques
 – IMT will be measured by B-mode ultrasound 
(Model IE33; Koninklijke Philips Electronics, 
Eindhoven, The Netherlands), using a linear ar-
ray transducer (L11-3 with a frequency up to 11 
MHz), with acquisition of multi-insonation angles 
for subsequent analysis with automated edge de-
tection software according to current guidelines.45
5. ECG for approximation of left ventricular hypertro-
phy (LVH)
 – ECG will be measured digitally (EC Sense Lexor; 
Cardiolex, Solna, Sweden). The following mea-
sures of LVH will be calculated:
 – Cornell voltage–duration product, defined as 
the sum of voltage of SV3 and RaVL multiplied 
by QRS duration (in women, 0.6 mV is added 
to the voltage).
 – Sokolow-Lyon voltage, defined as the sum of 
SV1 and R in V5 or V6, depending on which 
is larger.
6. Fundus photo to evaluate retinal vascular changes
 – Retinal vascular changes will be assessed through 
retinal imaging. Two methods will be employed to 
assess diabetic retinopathy and vascular damage:
 – Diabetic retinopathy will be graded using the 
Early Treatment of Diabetic Retinopathy Study 
classification.46 Grading is performed in seven 
standard fields. The assessed characteristics 
are graded in specific fields and/or multiple 
fields. The grading encompasses the following 
characteristics: microaneurysm, haemorrhag-
es, hard exudates, soft exudates, intraretinal 
microvascular abnormalities, venous abnor-
malities, new vessels on disc or elsewhere, pre-
retinal haemorrhage, vitreous haemorrhage, 
scars of prior photocoagulation and clinically 
significant macular oedema.
 – The retinal arteriolar and venular calibre as 
described by Hubbard et al.47 All venules and 
arterioles in the area half to one disc diame-
ter from the disc margin of the diameter are 
measured and an averaged measure is derived. 
The ratio of the venular and arteriolar diame-
ters also is derived.
 – Retinal photos will be taken after dilation of both 
eyes with one drop of 10% metaoxedrin and 
mydriacyl 5 mg/mL. After 10 min, this will be re-
peated. After a total of 20 min, six pictures will be 
taken of each eye.
 – All photographs will be assessed for retinopathy 
locally as part of the patients’ regular screening. 
Trained ophthalmologists at the Department of 
Ophthalmology, Odense University Hospital, then 
will assess retinopathy with the methods described 
above.
Surrogate marker evaluation will take place at baseline 
and again at 2 and 4 years of follow-up.
study interventions
Patients in the control group will not receive study-re-
lated interventions, but rather will be treated by their GP 
according to national guidelines. Patients in the inter-
vention group will receive multifactorial individualised 
treatment as outlined below. The outline of treatment will 
be subject to revision during the study if substantial new 
clinical evidence emerges. The suggested individualised 
treatment in the intervention group is made available 
to the treating GP, but the actual treatment is chosen at 
the discretion of the GP together with the patient. The 
intervention is designed to mimic the actual real-life 
effect of specialist treatment suggestions. Patients who 
do not follow the proposed algorithms are therefore not 
discontinued.
Antidiabetic treatment based on pathophysiological phenotypes
Pathophysiological phenotyping will provide the basis 
for individually guided treatment. At inclusion, patients 
with ‘other specific forms of diabetes’ will be identified. 
The remaining patients with classical WHO-defined T2D 
will be characterised according to their insulin sensitivity 
(IS) and beta-cell function (BCF). Of note, the subphe-
notyping and treatment of patients with WHO-defined 
T2D is constructed for patients of Caucasian inheritance 
(very few Danish citizens are non-Caucasian) and cannot 
readily be extrapolated to other ethnicities.
Other specific types of diabetes are defined as follows:
 ► Maturity-onset diabetes of the young (MODY). 
Patients will be screened for 10 monogenic causes of 
diabetes.
 ► Late autoimmune diabetes of the adult (LADA). 
Defined as GAD65-ab ≥20 IU/mL.
 ► Secondary diabetes. Defined as low BCF (HOMA2-
beta<115.3%) and a history of pancreatitis or pancreas 
resection.
 ► Steroid-associated diabetes, defined as use of oral 
glucocorticosteroids within 3 months of diabetes diag-
nosis. Genuine steroid-induced diabetes is present 
when it is known with certainty that diabetes was not 
present in the 3 months prior to steroid initiation. 
Patients with known prior T2D or with uncertainty 
about the timing of diabetes onset and steroid use 
will be allocated to one of the additional phenotypes 
described below.
Genuine WHO-defined T2D:
 ► Insulinopaenic T2D. Defined as low BCF (HOMA2-
beta<115.3%) and high IS (HOMA2-S≥63.5%).
 ► Classical T2D. Defined as low BCF (HOMA2-
beta<115.3%) and low IS (HOMA2-S<63.5%).
 ► Hyperinsulinaemic T2D. Defined as high 
BCF (HOMA2-beta≥115.3%) and low IS 
(HOMA2-S<63.5%).
The classification is hierarchical. The phenotypes have 
been described previously.25 BCF and IS will be assessed 
using the HOMA2 model, calculated based on fasting 
C-peptide and fasting plasma glucose. HOMA2-beta is an 
estimate of the BCF and HOMA2-S is an estimate of the 
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IS. In a healthy population without diabetes or impaired 
glucose tolerance, median HOMA2-beta was found to be 
115.3% and median HOMA2-S was 63.5%. In the study 
population, values of HOMA2-beta or HOMA2-S above 
these medians will be defined as ‘high’, while values 
below the median will be defined as ‘low’.
Proposed treatment strategies in the study according 
to diabetes phenotypes are as follows. The treatment 
proposed for each phenotype is additive, starting with A. 
B is added if the treatment goal is not reached, and so on.
1. MODY. (1) Types 1 and 3 MODY should be treated 
with glimepiride or repaglinid. (2) Type 2 MODY 
should be treated with diet. Secondarily, basal in-
sulin can be used. (3) Type 5 MODY should be 
treated with basal insulin. (4) Rare types of MODY 
should be treated individually according to specialist 
assessment.
2. LADA.
 – In patients who have IS and BCF equivalent to in-
sulinopaenic and classic T2D:
 – (A) Metformin if BMI >25 kg/m2. (B) Basal in-
sulin and meal-time insulin.
 – In patients who have IS and BCF equivalent to hy-
perinsulinaemic T2D:
 – Treatment equivalent to hyperinsulinaemic 
T2D (see below), with additional information 
on risk of rapid BCF deterioration and possi-
ble absolute need for insulin therapy.
3. Secondary diabetes. Basal and meal-time insulin.
4. Steroid-associated diabetes. (A) Meal-time insulin. 
(B) Metformin. (C) Basal insulin if fasting blood glu-
cose is above 7.0.
5. Insulinopaenic T2D. (A) Metformin. (B) Basal insu-
lin. (C) Meal-time insulin.
6. Classical T2D.
 – In patients without CVD: (A) Metformin. (B) GLP-1 
analogue*. (C) Basal insulin. (D) Meal-time insu-
lin.
 – In patients with former CVD: (A) Metformin. (B) 
SGLT-2 inhibitor. (C) GLP-1 analogue*. (D) Basal 
insulin. (E) Meal-time insulin.
7. Hyperinsulinaemic T2D. In patients with BMI >35 kg/
m2, gastric bypass should be considered according 
to current national criteria and patient preference. 
Pharmacological treatment:
 – In patients without CVD: (A) Metformin. (B) GLP-
1 analogue*. (C) Pioglitazone. (D) Basal insulin. 
(E) Meal-time insulin.
 – In patients with former CVD: (A) Metformin. (B) 
SGLT-2 inhibitor. (C) GLP-1 analogue*. (D) Piogl-
itazone. (E) Basal insulin. (F) Meal-time insulin.
Pioglitazone is not recommended for patients with 
heart failure, prior bladder cancer or known osteoporosis. 
If marked oedema develops, discontinuation of pioglita-
zone must be considered. Women should be informed 
about the increased risk of fractures with pioglitazone, 
alongside the reduced cardiovascular risk.
*DDP-4 inhibitors can be used if the patient does not 
want a GLP-1 analogue. It is recommended that a DDP-4 
inhibitor be discontinued if insulin is initiated.
In patients of Asian inheritance with WHO-defined 
T2D, incretin-based treatment can be considered as 
first-line treatment.48 Type of drug within drug classes, 
dosing and titration will be chosen at the discretion of the 
treating physician. Suggestive algorithms will be available 
to the physicians.
Treatment of hyperglycaemia will proceed according to 
the following individual goals:
 ► Optimal control of HbA1c <48 mmol/mol;
 ► Acceptable control of HbA1c <58 mmol/mol; or
 ► Free of symptoms, with best possible HbA1c achieved 
within this constraint.
All treatment algorithms will be applied according to 
these predetermined goals. GPs will be free to choose and 
reassess the goal applicable to an individual patient. In 
patients with neuropathy or pre-existing cardiovascular 
disease, careful goal assessment is needed. If a patient has 
a severe hypoglycaemic event, has repeated measures of 
blood glucose below 4.0 mmol/L or is therapy resistant, 
the goal should be reassessed. For an in-depth discussion 
of the motivation for the glucose-lowering algorithm, we 
refer to the online supplementary material.
Antihypertensive treatment
Treatment of hypertension will be guided by measure-
ments of thoracic impedance, which provide estimates 
of vascular resistance, intravascular volume and cardiac 
inotropy. These measurements will be used to guide the 
pharmacological treatment of arterial hypertension. Prin-
ciples of drug class choice will be as follows:
 ► When hypertension or microalbuminuria are present, 
patients should be treated with an ACE inhibitor (or 
a angiotensin-2 antagonist), regardless of the result of 
the impedance measurement.
 ► High vascular resistance, as the only abnormal 
impedance measure, should be treated with a calci-
um-channel blocker (CCB)(dihydropyridins) in addi-
tion to an ACE inhibitor.
 ► High intravascular volume, as the only abnormal 
impedance measure, should be treated with a thiazide 
in addition to current antihypertensive treatment. If 
the patient already is receiving a thiazide in maximum 
dose, an aldosterone receptor antagonist should be 
added.
 ► In cases of high vascular resistance and high intra-
vascular volume (more than double the vascular 
resistance in relative terms), diuretics (thiazide or 
secondarily aldosterone receptor antagonist) should 
be increased, comparable to the maximum dose of 
one new drug. As a next step, a CCB should be added. 
Finally, an aldosterone receptor antagonist should be 
increased to its maximum dose.
 ► In cases of high vascular resistance and high intra-
vascular volume (but less than double the vascular 
resistance in relative terms), an ACE inhibitor or 
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CCB should be added, depending on initial treat-
ment. As a second measure, diuretics (thiazide or, less 
often, an aldosterone receptor antagonist) should be 
increased comparable to the maximum dose of one 
new drug. As a third measure, CCB should be titrated 
to its maximum dose. Finally, an aldosterone receptor 
antagonist can be increased to its maximum dose.
 ► High inotropy is addressed only when the patient 
receives an ACE inhibitor, thiazide and CCB and the 
impedance measurement is made while the patient 
is receiving this treatment. Other abnormalities 
need to be addressed first. Carvedilol up to 50 mg is 
recommended.
The maximum dose of bendroflumethiazide is consid-
ered to be 5.0 mg, that for hydrochlorthiazide is 50 mg 
and that for spironolactone is 50 mg. In cases in which 
the estimated glomerular filtration rate (eGFR) is below 
30 mL/min/1.73 m2, high ceiling diuretics are substituted 
for thiazides. Non-hypertensive indications for antihyper-
tensive medication overrule this algorithm.
Impedance measurements also are used to downgrade 
antihypertensive treatment, in the following situations:
 ► When inotropy is decreased, beta-blockers are termi-
nated or the dose reduced.
 ► When hypovolaemia is present, diuretics are termi-
nated or the dose reduced.
 ► When inotropy is decreased, vascular resistance is 
normal and blood pressure is regulated, CCBs can be 
reduced or terminated.
For patients with prior cardiovascular disease, chronic 
kidney disease (eGFR <60 mL/min/1.73 m2) or albu-
minuria, the goal of antihypertensive treatment will be 
to achieve a blood pressure <130/80 mm Hg on three 
drugs, measured as home blood pressure or with an 
automated blood pressure device. For other patients, 
the goal is blood pressure <135/80 mm Hg on three 
drugs. In cases in which control of blood pressure is not 
achieved with three antihypertensive drugs, the patient 
will be referred to a specialist clinic. Blood pressure 
below 120/70 mm Hg should be avoided, if necessary by 
means of down-titration, unless other considerations are 
present.
Hypertension at study inclusion will be defined by pres-
ence of antihypertensive treatment or a blood pressure 
measurement above or equal to 135/80 mm Hg in the 
office under standardised conditions using an automated 
blood pressure device (Mobilograf).
Treatment of dyslipidaemia
Treatment with atorvastatin or simvastatin 40 mg will be 
recommended for all patients, regardless of the level 
of low-density lipoprotein cholesterol (LDL-C). If the 
treatment goal is not met, atorvastatin 80 mg or rosuvas-
tatin 40 mg will be recommended. Combining lipid-low-
ering drugs will not be recommended. The treatment 
goal will be LDL cholesterol ≤2.5 mM and LDL choles-
terol ≤2.0 mM in patients with established CVD.
Termination of inefficient medication
The effect of a specific antidiabetic, antihypertensive or 
cholesterol-lowering treatment will be measured. The 
following efficacy requirements after titration to the full 
tolerable dose will need to be met:
 ► Decline in HbA1c exceeding 0.5% within 3 months.
 ► Decline in systolic blood pressure exceeding 5 mm Hg 
within 1 month.
 ► Decline in LDL cholesterol exceeding 0.5 mM within 
1 month.
If the target is not met, the specific treatment should 
be terminated and replaced by another drug according 
to the algorithm. The missing effect on blood pressure 
should be validated by home blood pressure measure-
ments according to national guidelines. For antihyper-
tensive medication, another drug within the same class 
can be tried.
Lifestyle interventions
Supportive individualised M-health initiatives and face-
to-face consultations for promoting changes in lifestyle 
will be used in this study. The aim is to empower patients 
to achieve sustainable reductions in carbohydrate intake 
and increase the daily physical activity level.
In the current study, we will integrate dietician-sup-
ported self-management by using a commercially 
Internet platform (Liva) to facilitate interactive commu-
nication between dieticians and users, as well as by peer-
to-peer support. The platform will be further developed 
to support individualised education, goal setting and 
evaluation of diet and exercise behaviour as described 
below. In addition, interactive communication between 
patient and a personal healthcare professional will allow 
for asynchronous contact when needed, in the form of 
video, text or spoken messages. The advanced interac-
tive platforms will be supported further by an individu-
alised number of face-to-face consultations between the 
patient and the personal healthcare professional, with 
whom the patient will be acquainted from the interac-
tive platform.
The current study aims to empower patients to decrease 
the amount of carbohydrates in their diet (40% fat, 40% 
carbohydrates and 20% proteins), while keeping energy 
intake unchanged or slightly decreased in cases in which 
the patient seeks weight reduction. We will support 
individualised changes towards a sustainable increased 
number of low-carbohydrate meals each week. To support 
these changes, we have designed an Internet and smart-
phone platform (www. dd2mad. dk) that easily allows 
individuals to plan, purchase groceries and cook low-car-
bohydrate meals for all daily meals, including snacks. 
A dietician developed the recipes, and the macronutri-
tional composition of each recipe has been calculated 
using ‘DANKOST’ software (Dankost Aps, Copenhagen, 
Denmark). The platform is updated monthly with new 
recipes and will be developed further using a user-driven 
iterative process. We will implement this platform in the 
modified Liva.
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Table 2 Endpoint definitions 10th International Classification of Diseases (ICD-10) codes for diagnoses and operation codes 
were obtained from the Danish National Patient Registry, listed below)
Non-fatal myocardial infarction I21-23, T822A, T823 (without death within 30 days)
Coronary revascularisation KFNG, KFNA, KFNB, KFNC, KFND, KFNE, KFNF, KFNH, KFNW, KFLF
Cardiac arrest with resuscitation I46
Hospitalisation for heart failure I50, I11.0, I13.0+2 (only as a diagnosis)
Non-fatal stroke (including cerebral 
haemorrhage)
I61, I63, I64, KAAL10, KAAL11 (without death within 30 days)
Development of nephropathy BJFD2 (chronic dialysis) or
urine albumin–creatinine ratio >300 g/mg or
doubling of creatinine (if creatinine≥200 μM)
Development of retinopathy KCKC10, KCKC15 (laser therapy) or
DH360K and KCKD05B
KCKD65 (vitrectomy) or
H540+1+4 (blindness)
Severe hypoglycaemia leading to 
hospitalisation
E15, E160-2, T383A
Cancer (except basocellular carcinoma) C00-99 (except when ZM809xx are added)
Amputation of the lower limbs: KNEQ, KNFQ, KNGQ, KNHQ
Revascularisation procedures and 
peripheral thrombosis (not cardiovascular 
or cerebrovascular disease)
I74, N280, K550-1, K558-9, H340-2
KPBE+F+H+N+p+Q, KPBW, KPGH10, KPGE+F+H+N+p+Q, KPGW99, KPGW20, 
KPEE+F+H+N+p+Q+W, KPFE+H+n+P+Q+W, KPGH20+21+22+23+30+31+40+99, 
KPDU74+82+83+84, KPEU74+82+83+84, KPFU74+82+83+84, KPAE+F+H+N+p+Q, 
KPAW99, KPAU74, KPCE+F+H+N+p+Q, KPCW99, KPCW20, KPCU74+82+83+84, 
KPGU74+83+84+99, KPGW, KPWG
Fatal acute myocardial infarction I21-23, T822A, T823, R96-99 with death within 30 days
Fatal stroke I61, I63, I64 with death within 30 days
We aim to empower patients to make a sustainable 
increase in physical activity level by implementing interval 
walking. To enable the patients to engage in and maintain 
correct individualised interval walking, we have developed 
a smartphone application (InterWalk). The application 
is designed to individually guide duration and intensity 
of the training in real time based on a small test at the 
first use of the application. During use, the app automat-
ically monitors exercise intensity, training duration and 
walking distance. Following each training session, the app 
sends the data to a central server.49 The training data will 
be available for the patient and the healthcare profes-
sionals making it possible to provide evidence-based 
training feedback to patients, using physical fitness data,50 
training duration and compliance from the app.49 The 
InterWalk app will be implemented in the Liva platform. 
For a discussion of the motivation of the lifestyle interven-
tion, see the online supplementary material.
outcomes
The study’s primary outcome measure is time to a 
composite outcome of all-cause mortality, non-fatal 
myocardial infarction, coronary revascularisation, 
cardiac arrest with resuscitation, hospitalisation for heart 
failure, non-fatal stroke, development or progression of 
nephropathy or retinopathy (see below), severe hypogly-
caemia leading to hospitalisation and development of any 
cancer (except basocellular carcinoma). Development or 
progression of nephropathy is defined as renal failure 
(defined by the need for chronic dialysis), development 
of macroalbuminuria or doubling of baseline s-creatinine 
to a level above 200 μM. Development of retinopathy is 
defined as proliferative retinopathy or macular oedema 
that requires laser therapy, injection of vascular endo-
thelial growth factor inhibitors or vitrectomy, or diabe-
tes-related blindness (Snellen visual acuity below 0.1). 
Information on deaths will be obtained from the Civil 
Registration System. Individual diagnoses, operations 
and procedure codes will be obtained from the Danish 
National Patient Registry (see table 2). S-creatinine values 
and albumin–creatinine ratios will be obtained through 
the Danish Diabetes Database for Adults.
Secondary outcome measures are all-cause mortality, 
socioeconomic costs and quality of life. Quality of life will 
be assessed with SF-12 and Q-5 questionnaires at study 
inclusion and after 2 and 4 years.
Tertiary outcome measures are the individual endpoints 
in the composite endpoint. Other endpoints are
 ► Time to any macrovascular endpoint (as defined in 
the primary endpoint).
 ► Time to any microvascular endpoint (as defined in 
the primary endpoint).
 ► Time to fatal acute myocardial infarction.
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 ► Time to fatal stroke.
 ► Time to lower-limb amputation
 ► Time to other revascularisation procedures and 
peripheral thrombosis (not cardiac or cerebrovas-
cular events).
 ► Overall hospitalisations per 1000 patient-years.
 ► Treatment adherence, defined as reimbursement of 
prescriptions, compared with intended treatment 
dose: total yearly reimbursed doses versus intended 
yearly doses.
 ► Time trends of HbA1c, blood pressure and LDL 
cholesterol.
 ► Individual time trends of daily physical activity in 
intervention patients.
 ► Proportions of patients in the interventions group 
reaching their goal of HbA1c and blood pressure.
Cause of death will be obtained from the Danish Cause 
of Death Register. Reimbursement of prescriptions will 
be ascertained through the Danish National Prescrip-
tion Registry. Intended treatment dose will be obtained 
through the electronic medicine chart ‘FMK’.
power calculations
The power calculation was performed using Lakatos 
normal approximation for a log-rank test of two survival 
curves. The estimated sample size of 1123 patients will 
have 80% power to detect a reduction of 20% of the 
incidence rate of the primary endpoint, with a type 1 
error of 5%, during 10 years of follow-up. A composite 
yearly event rate of 5% is estimated, based on estimated 
incidence rates of 2.5% per year of macrovascular and 
microvascular complications, 1.5% per year for cancer 
and approximately 1% for overall mortality. The hypogly-
caemic event rate is expected to be less than 0.4%. Due 
to the database approach, loss to follow-up should be 
minimal.
statistical analysis
The advantage of our pragmatic study approach is that 
our results will reflect effectiveness, harms and costs of 
individualised treatment in daily practice in primary care, 
improving generalisability compared with single-exposure 
RCTs typically conducted among heavily selected patient 
and clinic populations. On the other hand, GP practices 
and their patients are self-selected to participating in the 
IDA intervention in our study and will be non-blinded to 
receiving this treatment. The main methodological chal-
lenge for our proposed study will therefore be to address 
possible confounding caused by imbalance of prognostic 
factors in participants versus controls. We will use appro-
priate statistical methods for dealing with confounding, 
including regression analyses and propensity score 
matching.
confounders
Covariates expected to be confounders will be selected 
according to available evidence and knowledge, and will 
include the following:
 ► General variables: age, gender, diabetes onset, DD2 
enrolment year, time from DD2 enrolment to IDA 
study entry, GP and place of residence (municipality).
 ► Lifestyle variables: smoking, alcohol consumption and 
physical exercise (self-reported).
 ► Comorbidity: each of the individual strata of the 
Charlson Comorbidity Index, except diabetes, hospi-
talisation for hypoglycaemia, chronic dialysis, laser 
treatment of retinopathy/maculopathy, vitrectomy, 
chronic heart disease, angina pectoris, any revascular-
isation procedure, lower-extremity amputation, atrial 
fibrillation and history of psychiatric disease (eight 
covariates defined by 10th International Classification 
of Diseases (ICD-10): DF1 to DF8).
 ► Socioeconomic variables: education, employment, 
income and social support.
 ► Clinical variables: blood pressure, BMI, waist circum-
ference, LDL-C, high-density lipoprotein choles-
terol (HDL-C), triglyceride level, creatinine level, 
urine albumin–creatinine ratio and diabetes 
phenotype.
 ► Medication use: aspirin, statins, anticoagulating drugs, 
thiazides, ACE inhibitors or angiotensin-2 antago-
nists, calcium channel antagonists, beta-blockers, 
potassium-sparing diuretics, metformin, sulfonylurea, 
DD4 inhibitors, GLP-1 analogues, SGLT-2 inhibitors, 
insulin, oral corticosteroids and number of redeemed 
drugs (including the above drugs).
Ascertainment of confounder variables will be through 
the DD2 cohort and registries. Comorbidity is defined as 
all diagnoses registered from 1977 until enrolment. Soci-
oeconomic variables are defined as the values recorded 
in the enrolment year. Medication use is defined as 
redeemed prescriptions 1 year prior to enrolment. Clin-
ical variables are defined by the value measured closest to 
enrolment, not more than 1 year prior to enrolment and 
1 month after enrolment.
cox regression analysis
Follow-up will extend for 10 years from the date of IDA 
intervention start until first of any of the individual 
composite outcome events, emigration out of Denmark 
or end of study (1 January 2028), whichever comes first. 
For patients in the control group, the entry date will be 
the date of DD2 enrolment or date of the overall IDA 
study initiation (1 January 2015), whichever comes last. 
We will construct survival curves for intervention and 
control patients and compute cumulative incidence rates. 
We then compute incidence rate ratios with 95% CIs 
for intervention patients compared with controls using 
Cox regression analysis and controlling for confounders 
described above. Stratified analyses will be performed by 
gender, age below/above 60 years, eGFR below/above 
60, former CVD and diabetes phenotype with test for 
interaction.
propensity score analysis
In a second analysis, we will use propensity score matching. 
For this analysis, we will compute the probability of each 
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DD2 cohort non-IDA-intervention patient being included 
in the IDA intervention arm in a logistic regression anal-
ysis, conditioned on the patient’s covariate profile. Next, 
we will match each intervention patient to a DD2 control 
patient with the closest propensity score in a 1:3 fashion 
and eliminate the remaining controls. The matching will 
be performed in a random sequential order. After deter-
mining that the covariates are balanced between the two 
treatment groups (see online supplementary material), 
we will conduct a matched Cox regression analysis without 
further adjustment. If any covariate is not balanced, a 
model with adjustment for non-balanced covariates will 
be made. The assumption of proportional hazards in the 
Cox models will be assessed graphically.
EtHIcs And dIssEMInAtIon
The study will use well-known pharmalogical agents and 
bariatric interventions. Thus, the safety of the patients is 
considered high. Patients in the intervention group will 
provide written informed consent before participation. 
The study will be conducted in compliance with the prin-
ciples set forth in the Declaration of Helsinki and the 
Good Clinical Practice Guidelines. The study has been 
approved by the Regional Committee on Medical Health 
Ethics (Region of Southern Denmark S-20120186), the 
Danish Data Protection Agency and the Danish Health 
and Medicines Authority (journal no. 2012120204).
All subjects will be identified by an unambiguous 
subject code that can be linked to the civil registration 
number. The subject code will be used as a pseudoanony-
misation code throughout the study. Handwritten source 
data (CRFs) or hard-copy source data will be securely 
safeguarded against unauthorised access and kept under 
lock, with access only by authorised persons. Electroni-
cally reported source data will conform to good clinical 
practice standards by using the RedCap data collection 
system and the DD2-established data collection system. 
Both systems have a high level of security and use data 
verification and detailed logging during reporting.
Most study data will be stored in OPEN, a custom-designed 
study database secured against unauthorised access. OPEN 
is a research service provided by the University of Southern 
Denmark that enables researchers to store research data in 
accordance with national legislation and requirements for 
data logging, password security and backup.
Study results will be made public via articles in national and 
international peer-reviewed journals, which will be accessible 
online https:// dd2. nu). Positive, negative and inconclusive 
results will be published according to the Vancouver Princi-
ples. The results will be disseminated through www. clinical-
trials. com and the Danish Diabetes Association.
pErspEctIvEs
IDA is one of the first studies to formalise a specific 
implementation of individualised medicine in treating 
T2D. The ultimate goal is to improve quality of life and 
reduce complications in patients with T2D—in a manner 
requiring less medication and fewer resources over a 
10-year period.
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